Life Insurance After Prostate Cancer: Gleason Score, PSA, Treatment & Rate Classes

Big Lou

7 days ago

11 min read

Prostate Cancer and Life Insurance — Quick Answer

Yes. Many men who have been treated for prostate cancer can still qualify for traditional life insurance, and some low-risk cases can qualify for very favorable rate classes.

The diagnosis alone does not determine the rate. Underwriters care about the exact Gleason score or Grade Group, stage, PSA before treatment, treatment method, PSA after treatment, whether the cancer recurred, how much time has passed, and the rest of your health profile.

A prostate cancer diagnosis is not a rate class. The details of the cancer are the underwriting story.

That matters because two men can both say, "I had prostate cancer," and still receive very different underwriting decisions.

What Life Insurance Underwriters Actually Want to Know

Before Big Lou thinks about a carrier or a quote, we want the same details an experienced underwriter will want:

· Age at diagnosis

· Exact Gleason score and Grade Group

· Clinical and, if available, pathological stage

· PSA level before treatment

· Treatment type - radical prostatectomy, external-beam radiation, brachytherapy, proton therapy, active surveillance, hormone therapy, or a combination

· Date treatment was completed

· Current PSA and the PSA trend since treatment

· Pathology details after surgery, including margins, lymph nodes and whether disease extended beyond the prostate

· Any evidence of recurrence, salvage radiation, additional hormone therapy or metastatic disease

· Current follow-up with the urologist or oncologist

· Other health issues such as coronary disease, diabetes, smoking, kidney disease and weight

The more complete that picture is before an application is submitted, the better chance there is of choosing the right underwriting path instead of simply chasing the lowest advertised quote.

Gleason Score: Why 3+4 and 4+3 Are Not the Same

This is one of the most important details in prostate-cancer underwriting.

The Gleason score combines the two dominant microscopic patterns seen in the tumor. The first number is the pattern seen most often. That means a Gleason 7 is not one single risk category.

Gleason / Grade Group	What it generally means medically	Life insurance underwriting direction
3+3=6 / Group 1	Low grade; the least aggressive commonly assigned Gleason score.	Most favorable prostate-cancer category, especially when organ-confined and successfully treated.
3+4=7 / Group 2	Mostly pattern 3 with a smaller amount of pattern 4.	Usually viewed more favorably than 4+3. Carrier, stage, treatment and follow-up still matter.
4+3=7 / Group 3	Mostly pattern 4, which is more aggressive than pattern 3.	Meaningfully tougher than 3+4 despite the same total score of 7.
8-10 / Groups 4-5	High-grade disease with greater risk of recurrence or spread.	More conservative underwriting, longer stability periods and more limited carrier options are common.

3+4 and 4+3 both add up to 7. Underwriters do not view them as the same cancer risk.

A man with Gleason 3+4 disease has more pattern 3 than pattern 4. A man with Gleason 4+3 disease has more pattern 4. That difference is why modern pathology reports also use Grade Groups: 3+4 is Grade Group 2, while 4+3 is Grade Group 3.

For life insurance, that can affect how long a carrier wants to see stable follow-up and whether the eventual offer is Standard, table-rated or potentially better.

Stage Matters Just as Much as the Gleason Score

A low Gleason score is helpful, but the cancer also needs context. Underwriters want to know whether it was confined to the prostate or had moved outside it.

· T1-T2 disease is generally organ-confined and is usually the most favorable staging territory.

· T3 disease means the tumor has extended outside the prostate and is underwritten more cautiously.

· Lymph-node involvement (N1) materially changes the risk picture.

· Distant metastatic disease (M1) is a very different underwriting category and is generally not a traditional term-life case while active or recently treated.

Surgical pathology can be especially valuable because it may give the underwriter a more complete picture than the biopsy alone, including margin status, seminal-vesicle involvement and lymph-node findings.

PSA Before Treatment Matters - But PSA After Treatment Often Matters More

PSA is one of the most important markers in prostate-cancer underwriting. The underwriter usually wants to know the PSA at diagnosis or before treatment, then compare that with what happened after treatment.

In general, a lower pre-treatment PSA combined with low-grade, organ-confined disease is a more favorable starting point than a very high PSA or a rapidly rising PSA.

But once treatment is complete, the PSA response becomes critical. And this is where the treatment method changes the meaning of the number.

Radical Prostatectomy vs. Radiation: The PSA Rules Are Different

Treatment	What doctors expect from PSA	What underwriters usually want to see
Radical prostatectomy	Because the prostate has been removed, PSA should fall to a very low or undetectable level, usually checked after the post-operative recovery period.	Serial undetectable or essentially undetectable PSA results, favorable pathology, no recurrence and adequate follow-up.
Radiation / brachytherapy	The prostate remains in the body, so PSA is not expected to go to zero. It usually falls more slowly toward a nadir.	A low, stable PSA trend over time, no concerning rise from the nadir, no evidence of recurrence and appropriate oncology follow-up.

After surgery, "undetectable" is the goal. After radiation, "zero" is not the goal - the PSA nadir and trend are what matter.

People often tell us their PSA is "zero" after prostatectomy. In practice, the laboratory may report something such as <0.01, <0.02 or another assay-specific undetectable value. For underwriting, the important point is that the PSA reached an appropriately undetectable level and stayed there.

After radiation, the situation is different because normal prostate tissue remains and can continue to produce PSA. The PSA can take many months, and sometimes longer, to reach its lowest point. A temporary "PSA bounce" can also occur. Underwriters therefore look closely at the trend, not just one isolated number.

Medical guidelines commonly define biochemical recurrence after radiation as a PSA rise of 2.0 ng/mL or more above the post-treatment nadir. Insurance companies do not have to wait for that medical threshold before becoming cautious; a rising trend can still affect underwriting.

Treatment Type Changes the Underwriting Story

Radical Prostatectomy

For a low-grade, organ-confined cancer, surgery can give an underwriter a very clean set of facts: the prostate was removed, final pathology is available, margins and lymph nodes can be reviewed, and PSA should become undetectable.

A favorable case might include Gleason 6, organ-confined disease, negative margins, negative lymph nodes, no salvage treatment and serial undetectable PSA results.

Radiation, Proton Therapy or Brachytherapy

Radiation can be highly effective, but underwriting follow-up is different because PSA usually declines more slowly and does not need to become undetectable. The carrier may want a longer pattern of stable or declining PSA results before offering its best terms.

If androgen-deprivation therapy was also required, the underwriter will ask why. In some cases it is part of a standard radiation protocol; in others it can signal higher-risk disease. Context matters.

Active Surveillance

Some men with very low-risk or low-risk prostate cancer do not receive immediate surgery or radiation. Instead, the cancer is monitored with PSA testing, imaging and repeat biopsies as appropriate.

Life insurance may still be possible during active surveillance, but the cancer is technically still present. Carrier appetite varies widely. Age, PSA trend, Grade Group, number of positive biopsy cores, MRI findings and the quality of follow-up can all become important.

Salvage Radiation or Recurrence Treatment

If PSA begins to rise after prostatectomy and a man needs salvage radiation, or if cancer recurs after initial treatment, underwriting becomes more conservative. The key questions become why the recurrence occurred, whether treatment was successful, what the PSA is doing now and how much stable time has passed since the additional treatment.

Can You Get Preferred Life Insurance Rates After Prostate Cancer?

Sometimes, yes - but this is where generic internet advice gets sloppy.

A history of prostate cancer does not automatically cap every applicant at Standard forever. Some carrier underwriting programs allow Preferred consideration for selected prostate-cancer histories. The criteria can be narrow and they change over time.

The strongest Preferred-type profile is usually something like:

· Low-grade disease, commonly Gleason 6 / Grade Group 1

· Organ-confined disease with favorable pathology

· Lower pre-treatment PSA

· Definitive treatment with no evidence of residual disease

· Undetectable PSA after radical prostatectomy, or a very favorable stable PSA pattern after radiation

· No recurrence or salvage treatment

· Enough time since treatment to satisfy that carrier's guidelines

· Otherwise excellent health for the applicant's age

Age can matter too. Some insurers have historically given particularly favorable consideration to older men with low-risk prostate cancer because the long-term mortality risk can look very different from the same diagnosis at a much younger age.

For the right low-risk case, "I had prostate cancer" does not automatically mean Standard or table-rated. Select carriers may consider Preferred.

That is exactly why carrier selection matters. A quote engine usually knows your age, gender and smoking status. It does not know your final pathology, PSA nadir or the difference between 3+4 and 4+3 unless someone actually underwrites the story.

A Practical Underwriting Outlook by Risk Profile

These are not promises or universal carrier rules. They are a practical way to understand why two prostate-cancer survivors can receive very different offers.

Profile	Typical underwriting direction	What can improve the case
Gleason 6 / Grade Group 1, organ-confined, excellent follow-up	Often the most favorable. Standard or better can be possible; select carriers may consider Preferred.	Undetectable/stable PSA, clean pathology, more time since treatment, strong overall health.
Gleason 7, 3+4 / Grade Group 2	Often insurable, but more likely to require carrier-specific review and possibly a rating.	Organ-confined disease, favorable treatment response, stable PSA, longer disease-free interval.
Gleason 7, 4+3 / Grade Group 3	Usually underwritten more cautiously than 3+4. Table ratings or longer wait periods are more common.	Favorable stage, successful treatment, stable PSA over time, no recurrence.
Gleason 8-10, node-positive, recurrent or metastatic history	More limited traditional options and often significant postponement or ratings.	Longer proven stability, successful completion of treatment and no evidence of recurrence.

Three Prostate Cancer Cases That Sound Similar - But Are Not

Case 1: Low-Risk Surgical Case

A 68-year-old man had Gleason 6 / Grade Group 1 prostate cancer confined to the prostate. He underwent radical prostatectomy. Margins and lymph nodes were negative, and his PSA has remained undetectable on repeated follow-up.

Underwriting direction: This is the type of history that can be very competitive. Depending on time since treatment, age and the rest of his health, Standard or better may be realistic, and select carriers may consider Preferred.

Case 2: Gleason 7, 3+4 After Radiation

A 64-year-old man had Gleason 3+4 / Grade Group 2 disease treated with radiation. His PSA fell gradually after treatment and has remained low and stable, with no evidence of recurrence.

Underwriting direction: Coverage may be very possible, but the carrier will care about the full PSA trend, stage, time since treatment and whether hormone therapy was used. A Standard or table-rated offer may be more realistic than Preferred, although carrier differences can be meaningful.

Case 3: Gleason 7, 4+3 With Rising PSA

A 62-year-old man had Gleason 4+3 / Grade Group 3 disease, underwent surgery, and later developed a rising PSA that required salvage radiation.

Underwriting direction: This is a materially different risk than Case 1 or Case 2. The carrier is likely to focus on the recurrence, response to salvage treatment and the length of stable follow-up before considering a competitive traditional offer.

Same diagnosis: prostate cancer. Completely different underwriting stories.

How Long Do You Have to Wait After Prostate Cancer Treatment?

There is no honest one-size-fits-all answer.

Some favorable low-risk surgical cases can be considered relatively soon after treatment by certain carriers. Other cases need one, two, five or more years of stable follow-up before the pricing becomes attractive. Higher Gleason scores, higher stage, radiation-based treatment, recurrence, salvage therapy and younger age at diagnosis can all lengthen the runway.

The mistake is assuming that every carrier has the same waiting period. They do not.

Sometimes the best answer is to apply now. Sometimes the better answer is to keep existing coverage and wait for one more PSA result or another year of clean follow-up. A good impaired-risk strategy should be willing to tell you both.

What to Have Ready Before You Apply

You do not need to walk into the first conversation carrying a medical chart. But the more of the following you can identify, the more accurate the underwriting discussion can be:

· Pathology report showing Gleason score / Grade Group

· Clinical stage and final surgical stage if you had prostatectomy

· PSA at diagnosis

· Date and type of treatment

· Post-treatment PSA results with dates

· Operative pathology including margins and lymph-node status, if applicable

· Radiation oncology summary, if applicable

· Any hormone therapy and whether it is complete

· Any recurrence or salvage treatment

· Most recent urology or oncology follow-up

For Big Lou, this is not paperwork for the sake of paperwork. These are the facts that can determine which insurance company deserves the first application.

The Big Lou Difference: Shop the Underwriting Before You Shop the Price

If you had prostate cancer, the cheapest Preferred Plus quote on a website is almost meaningless until someone decides whether Preferred Plus, Preferred, Standard or a table rating is actually realistic for your case.

The better sequence is:

1. Understand the pathology.

2. Understand the PSA history.

3. Understand the treatment and follow-up.

4. Identify which carriers are most comfortable with that exact profile.

5. Then compare price inside the rate class you can realistically earn.

We don't just shop prices. We shop underwriting.

Helpful Big Lou Resources

Life Insurance Rate Classes Explained - Understand Preferred, Standard and table ratings before you compare prices.

Get an Underwriting Second Opinion - Already rated, postponed or declined? Keep the offer and find out whether another carrier may view the case differently.

Who Is Big Lou? - Why Big Lou focuses on real health histories instead of mythical rates.

Frequently Asked Questions

Can I get life insurance after prostate cancer?

Yes, many prostate-cancer survivors can qualify for traditional life insurance. The rate and timing depend on the Gleason score, stage, treatment, PSA history, recurrence risk, time since treatment and overall health.

Can I get Preferred rates after prostate cancer?

Potentially. Select carriers may consider Preferred for carefully selected low-risk prostate-cancer histories, particularly when the disease was low grade, organ-confined, successfully treated and followed by excellent PSA results. It is not automatic and the carrier criteria can be narrow.

Is Gleason 3+4 the same as 4+3 for life insurance?

No. Both total 7, but 3+4 is Grade Group 2 and has more pattern 3 disease. 4+3 is Grade Group 3 and has more pattern 4 disease, which is more aggressive. Underwriters generally view 4+3 more cautiously.

What PSA does a life insurance company want after prostatectomy?

The strongest post-prostatectomy history is an appropriately undetectable PSA that stays undetectable on serial follow-up. The exact reported number depends on the laboratory assay. Underwriters also care about stage, margins, lymph nodes and whether any salvage treatment was needed.

Does PSA need to be zero after radiation?

No. Radiation leaves the prostate in place, so some PSA production is expected. Underwriters generally care about the PSA nadir and whether the PSA remains low and stable over time, rather than requiring the same undetectable result expected after prostatectomy.

Can I get life insurance while on active surveillance?

Sometimes. Low-risk prostate cancer under active surveillance can be insurable, but carrier appetite varies because the cancer has not been definitively treated. PSA trend, Grade Group, biopsy findings, MRI results, age and quality of follow-up all matter.

What if my prostate cancer came back?

Recurrence does not automatically mean you will never qualify, but it changes the underwriting significantly. A rising PSA, salvage radiation, additional hormone treatment or metastatic recurrence can require a longer period of demonstrated stability and may limit traditional carrier options.

Had Prostate Cancer? Start With the Pathology, Not the Quote.

Tell Big Lou the Gleason score, treatment, PSA history and when treatment ended. We can help you think through what rate class is realistic and which underwriting path may make the most sense before you commit to an application.

Get a Realistic Life Insurance Quote

https://www.bigloulife.com/getquote

No pressure. No obligation. Real underwriting before mythical pricing.

Important Disclaimer

This article provides general educational information about life insurance underwriting and prostate cancer. It is not medical advice and is not a guarantee of eligibility, approval, rate class, premium or carrier availability. Underwriting guidelines change and vary by insurance company, product, state, age and individual medical history. Medical definitions and treatment decisions should be discussed with your healthcare provider. Do not alter treatment or follow-up in an attempt to affect a life insurance application.